Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

April 20, 2018April 20, 2018

#AAN2018 – Switching from Rebif to Ocrevus Improves MS, Extension Study Shows

News

Continuous treatment with Ocrevus (ocrelizumab) or switching from Rebif (interferon beta-1a) to Ocrevus leads to a significant long-term reduction in relapsing multiple sclerosis activity, a two-year extension study ... Read more

April 19, 2018April 19, 2018

#AAN2018 – Biogen Data Covers Work into an MS Blood Biomarker, Cognition and Life Quality

News

Research that points to a potential blood biomarker of multiple sclerosis (MS) severity, relates cognitive difficulties to patients’ employment and other measures of socioeconomic status, and one-year results ... Read more

April 19, 2018April 19, 2018

#AAN2018 — Investigational Therapy Ibudilast Slows Brain Atrophy in Phase 2 Trial for Progressive MS

News

Investigational therapy ibudilast leads to a significant reduction of brain atrophy, supporting its potential to effectively treat progressive multiple sclerosis (MS), new data from a Phase 2 clinical ... Read more

April 18, 2018April 18, 2018

#AAN2018 – Ocrevus Decreases Biomarkers of MS Patients’ Nerve Cell Damage, Phase 3 Trial Shows

News

Genentech’s Ocrevus (ocrelizumab) reduces levels of cerebrospinal fluid biomarkers that denote nerve cell damage in multiple sclerosis patients, a Phase 3 clinical trial shows. Researchers will present the ... Read more

April 16, 2018April 17, 2018

Adverse Effects Influence Patient’s Perspective of Ocrevus’s Effectiveness, Survey Shows

News

Higher rates of adverse effects have a negative impact on a patient’s perspective about treatment with Ocrevus (ocrelizumab), according to a survey conducted by the multiple sclerosis community GeneFo. ... Read more

April 13, 2018April 13, 2018

Acute Acalculous Cholecystitis Linked to Lemtrada Use in RRMS Patients, FDA Reports

News

Acute acalculous cholecystitis (AAC) is a rare but potentially life-threatening adverse effect linked to treatment with Lemtrada (alemtuzumab) in patients with relapsing-remitting multiple sclerosis (RRMS), according to ... Read more

April 3, 2018April 3, 2018

Study Receives $1.7M from NIH to Research New Therapeutic Strategies for MS, Others

News

A new project aimed at boosting the development of new therapies for multiple sclerosis (MS) and other demyelinating diseases recently won $1.7 million in funding from ... Read more

March 29, 2018March 30, 2018

GeNeuro-Servier Antibody Limits RRMS Patients’ Brain Shrinkage, Phase 2b Trial Shows

News

The laboratory-generated antibody GNbAC1 continued to limit brain shrinkage a year after relapsing-remitting multiple sclerosis patients began receiving it, its developers announced. GeNeuro and Servier were reporting on the 12-month ... Read more

March 27, 2018March 29, 2018

Smoking Increases Relapses in RRMS Patients Receiving Interferon-beta, Study Suggests

News

Cigarette smoking increases the relapse rate in patients with relapsing-remitting multiple sclerosis who are being treated with interferon-beta, a study suggests. The findings suggest that RRMS ... Read more

March 23, 2018March 23, 2018

Emerald’s Cannabinoid-derived EHP-101 Enhances Remyelination in 2 MS Mouse Models

News

Emerald Health‘s investigational cannabidiol-derived EHP-101 reduces neuroinflammation, the risk of loss of myelin, and nerve cell damage in two mouse models of multiple sclerosis (MS), a new ... Read more

March 21, 2018March 27, 2018

Blood Stem Cell Transplants Improve RRMS Patients’ Disability, Phase 3 Trial Shows

News

Blood stem cell transplants lead to significant improvements in relapsing-remitting multiple sclerosis patients’ disability, a Phase 3 clinical trial shows. The 110 patients who took part in ... Read more

March 15, 2018March 15, 2018

New Spherix Report Finds PPMS Treatment Increased Significantly in Past Year

News

Since Genentech‘s Ocrevus was approved a year ago, the treatment rate of primary progressive multiple sclerosis (PPMS) has increased significantly. However, a closer look at the data shows that other ... Read more

March 9, 2018March 9, 2018

Merck’s MS Therapy Evobrutinib Significantly Reduces Brain Lesions, Phase 2 Trial Shows

News

Merck KGaA’s evobrutinib led to significant reductions in relapsing multiple sclerosis patients’ brain and spinal cord lesions, compared with a placebo, a Phase 2b clinical trial showed. ... Read more

March 8, 2018March 15, 2018

Increase in Blood-Brain Barrier Protein May Protect Against MS, Study Finds

News

One way the body may protect itself from nerve cell inflammation is to have cells in the blood-brain barrier increase their production of a protein that ... Read more

February 28, 2018February 28, 2018

Inhibiting Oxidative Stress Enzyme Reduces Nerve Cell Damage in Mice with MS, Study Shows

News

Inhibiting an oxidative stress enzyme reduced nerve cell damage and promoted the formation of new nerve cells, a multiple sclerosis study in mice showed. It also helped ... Read more

February 27, 2018March 1, 2018

Transforming Skin Cells Into Nerve Stem Cells Could Be a Way to Treat MS, Study Suggests

News

Reprogramming skin cells into brain stem cells, then transplanting them into the central nervous system may reduce inflammation and reverse the nerve cell damage in progressive ... Read more

February 19, 2018February 19, 2018

New Ocrevus Data, Post-FDA Approval, Supports Range of Benefits, Genentech’s Hideki Garren Says

News

Ocrevus (ocrelizumab), Genentech’s humanized anti-CD20 monoclonal antibody, continues to show clear evidence that it helps to slow disease progression and enable better function — including in the hands ... Read more

February 16, 2018February 16, 2018

Inhibiting Enzyme Can Reverse Myelin Damage, Improve Limb Function, Mouse Study Shows

News

Inhibiting an enzyme responsible for turning genes on and off can reverse damage to the myelin sheath that protects nerve cells, improving limb function, a multiple ... Read more

February 14, 2018February 15, 2018

Italian Study Examines Tysabri and Risk for Miscarriage and Birth Defects

News

Pregnant women with multiple sclerosis exposed to Tysabri in the first trimester had higher rates of miscarriage and major birth defects in their babies, than women ... Read more

February 12, 2018February 12, 2018

Australian Researchers Identify Master Regulator of the Faulty Inflammation Signaling in MS

News

Australian researchers have identified the master regulator of the immune response signaling pathway that is out of sync in multiple sclerosis and other inflammatory diseases. The ... Read more

February 9, 2018February 9, 2018

#ACTRIMS2018 – Third Course of Lemtrada Improves Relapse, Disability in MS Patients, CARE-MS II Trial Shows

News

Multiple sclerosis (MS) patients who experience a relapse after two courses of Lemtrada (alemtuzumab) treatment showed improvements in relapse rate and disability after a third Lemtrada course, according to results ... Read more

February 8, 2018February 8, 2018

#ACTRIMS2018 – MS Therapy MD1003’s Disability Improvements Hold Over Time, Study Shows

News

MedDay Pharma’s MD1003 leads to long-lasting improvements in progressive multiple sclerosis patients’ disability, a Phase 3 clinical trial follow-up study shows. Researchers presented the results at the third Annual ... Read more

February 7, 2018February 7, 2018

Adamas Therapy Improves Multiple Sclerosis Patients’ Walking Speed, Trial Shows

News

The walking speed of multiple sclerosis patients taking Adamas Pharmaceuticals’ ADS-5102 (amantadine) increased by 16.6 percent more those taking a placebo, a Phase 2 clinical trial reports. ... Read more

February 5, 2018February 5, 2018

#ACTRIMS2018 – Extending Tysabri Treatment Intervals May Reduce PML Risk, TOUCH Registry Data Suggest

News

Extending the dosing periods of Tysabri (natalizumab) treatment may help reduce the risk of progressive multifocal leukoencephalopathy, or PML, in multiple sclerosis (MS) patients infected with ... Read more

February 2, 2018February 2, 2018

#ACTRIMS2018 – MediciNova Presents Positive Results from SPRINT-MS Trial Evaluating Ibudilast in Progressive MS

News

Top-line results from a clinical trial evaluating the investigational oral therapy ibudilast for progressive multiple sclerosis (MS) show that the therapy led to a significant reduction ... Read more

January 31, 2018February 1, 2018

RRMS Patients Say Both Rebif Rebidose and Rebiject Are Easy to Use

News

When choosing between the single use autoinjector Rebif Rebidose or the reusable autoinjector Rebiject II, patients with relapsing-remitting multiple sclerosis found both easy to very easy ... Read more

January 31, 2018February 1, 2018

#ACTRIMS2018 – Oryzon Enrolls First Patient in SATEEN Trial, Presents New Data at MS Meet

News

Oryzon Genomics has enrolled the first multiple sclerosis patient in its Phase 2a SATEEN clinical trial investigating the therapy ORY-2001. The Spanish company will also present new results ... Read more

January 30, 2018January 31, 2018

#ACTRIMS2018 – Ublituximab Led to Major Drop in MS Brain and Spine Lesions, Trial Shows

News

TG Therapeutics‘ ublituximab (TG-1101) led to a remarkable reduction in multiple sclerosis patients’ brain and spine lesions, a Phase 2 clinical trial showed. In fact, none of ... Read more

January 24, 2018January 31, 2018

MS Patients’ High Osteopontin Protein Levels Make It a Potential Biomarker for the Disorder, Study Reports

News

Multiple sclerosis patients have high levels of a protein called osteopontin in their cerebrospinal fluid and blood, making it a potential tool for diagnosing the disease ... Read more

January 23, 2018January 25, 2018

Non-Hispanic Women Have Highest MS Mortality Rates, But Blacks Die Earlier, USC Survey Finds

News

Non-Hispanic whites, especially females, are more likely to die from multiple sclerosis (MS) than any other racial group, though blacks tend to die earlier, concludes a ... Read more

January 19, 2018January 19, 2018

Loss of Deep Grey Matter in Brain Linked to Greater Disability, MS Progression in Study

News

Deep grey matter volume loss in the brain drives multiple sclerosis (MS) progression and disability, and is particularly evident in people with progressive forms of the ... Read more

January 18, 2018January 18, 2018

Excessive Salt Consumption Leads to Cognitive Impairment, MS Mouse Study Shows

News

New research shows how a high-salt diet leads to excessive levels of interleukin-17 (IL-17) in multiple sclerosis (MS) patients, causing changes in endothelial cells that result ... Read more

January 16, 2018January 16, 2018

Long-term Rituxan Treatment Is Effective and Safe in MS, Study Shows

News

The approved lymphoma therapy Rituxan (rituximab) has shown promise as a treatment for  multiple sclerosis. A new study indicates the Genentech treatment is effective and safe ... Read more

January 5, 2018January 5, 2018

Human Herpes Virus 6 May Increase Risk of MS, Study Suggests

News

Iranian researchers have identified another herpes virus that may increase the risk of a person developing multiple sclerosis. The team identified the human herpesvirus 6, or ... Read more

January 4, 2018January 4, 2018

GSK Researchers Identify Potential Target for Therapeutics to Promote MS Remyelination

News

Researchers at GlaxoSmithKline (GSK) have identified the histamine receptor 3 (H3R) as a potential new therapeutic target for promoting remyelination in patients with multiple sclerosis (MS). Their study ... Read more

January 2, 2018January 2, 2018

Gilenya Halts Brain’s Gray Matter Atrophy in RRMS Patients, Study Suggests

News

Treatment with Gilenya (fingolimod) may limit cerebral gray matter atrophy in relapsing-remitting multiple sclerosis (RRMS) patients, researchers at Boston’s Brigham and Women’s Hospital have found. Their report, ... Read more

December 29, 2017December 22, 2017

Clomipramine, an Antidepressant, Shows Potential in Treating Progressive MS in Early Study

News

Clomipramine, an approved antidepressant, shows potential in treating people with progressive multiple sclerosis (MS)  — a disease form with few treatments — by protecting nerves from ... Read more

December 28, 2017December 21, 2017

Zinbryta Fails to Prevent RRMS from Worsening After Patient Gets Off Tysabri, Case Study Shows

News

Zinbryta (daclizumab) may not be the best follow-up therapy for relapsing–remitting multiple sclerosis patients who stop taking Tysabri (natalizumab) for safety reasons, a case study suggests. ... Read more

December 19, 2017December 19, 2017

Additional Diseases Increase Risk of MS Relapses, Canadian Study Shows

News

Multiple sclerosis patients with additional diseases, high cholesterol levels or a history of migraine headaches are more likely to experience relapses than other patients, a Canadian ... Read more

December 14, 2017December 14, 2017

Body’s Biological Clock and Time of Day Affects Immune Cells, Mouse Study Shows

News

Researchers further explored how our internal biological clock — known as circadian rhythm — influences immune system responses. Disruptions to that rhythm are associated with immune diseases ... Read more